TLR2 and Parkinson disease: To establish this effect in a PD midbrain model, differentiated cells were treated with 1 μg/ml of TLR2 agonist Pam3CSK4 and/or 1 μg/ml α-syn PFFs, and α-syn pathology markers measured on days 7 and 14 of treatment.